Cargando…

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020

IMPORTANCE: Of approximately 9 million patients with cancer in China in 2020, more than half were diagnosed with late-stage cancers. Recent regulatory reforms in China have focused on improving the availability of new cancer drugs. However, evidence on the clinical benefits of new cancer therapies a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yichen, Naci, Huseyin, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen, Guan, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366546/ https://www.ncbi.nlm.nih.gov/pubmed/35947385 http://dx.doi.org/10.1001/jamanetworkopen.2022.25973

Ejemplares similares

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021
por: Zhou, Yue, et al.
Publicado: (2023)

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
por: Davis, Courtney, et al.
Publicado: (2017)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data
por: Yang, Yu, et al.
Publicado: (2023)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
por: Azevedo, M.C., et al.
Publicado: (2014)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database
por: Bai, Lin, et al.
Publicado: (2020)

Prescription Stimulant Medical and Nonmedical Use Among US Secondary School Students, 2005 to 2020
por: McCabe, Sean Esteban, et al.
Publicado: (2023)

Availability of New Medicines in the US and Germany From 2004 to 2018
por: Blankart, Katharina, et al.
Publicado: (2022)

Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan
por: Maeda, Hideki, et al.
Publicado: (2023)

Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States
por: SALCHER‐KONRAD, MAXIMILIAN, et al.
Publicado: (2020)

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011–2021
por: Bai, Lin, et al.
Publicado: (2023)

Overall and Cervical Cancer Survival in Patients With and Without Mental Disorders
por: Herweijer, Eva, et al.
Publicado: (2023)

Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending
por: Huang, Tao, et al.
Publicado: (2021)

Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020
por: Liang, Yu-Jing, et al.
Publicado: (2022)

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023)

Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer
por: Tobias, Claire J., et al.
Publicado: (2020)

Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival
por: Yang, Daniel X., et al.
Publicado: (2021)

Overall Survival After Treatment Failure Among Patients With Rectal Cancer
por: Diefenhardt, Markus, et al.
Publicado: (2023)

Medication Use During Pregnancy in Mainland China: A Cross-Sectional Analysis of a National Health Insurance Database
por: Zhang, Jingyuan, et al.
Publicado: (2019)

Changes in Incidence and Epidemiological Characteristics of Pulmonary Tuberculosis in Mainland China, 2005-2016
por: Jiang, Hui, et al.
Publicado: (2021)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

Functional connectivity within glioblastoma impacts overall survival
por: Daniel, Andy G S, et al.
Publicado: (2020)

MRI phenotypes of glioblastomas early after treatment are suggestive of overall patient survival
por: Schmitz-Abecassis, Bárbara, et al.
Publicado: (2023)

Estimated Burden of Stroke in China in 2020
por: Tu, Wen-Jun, et al.
Publicado: (2023)

Survival Benefit of Living-Donor Liver Transplant
por: Jackson, Whitney E., et al.
Publicado: (2022)

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Lin, Jian-Xian, et al.
Publicado: (2022)

Assessment of NO(2) population exposure from 2005 to 2020 in China
por: Huang, Zhongyu, et al.
Publicado: (2022)

Association of Hospital-Level Acute Resuscitation and Postresuscitation Survival With Overall Risk-Standardized Survival to Discharge for In-Hospital Cardiac Arrest
por: Girotra, Saket, et al.
Publicado: (2020)

Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma
por: Sebastian, Nikhil T., et al.
Publicado: (2019)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study
por: Guan, Xiaodong, et al.
Publicado: (2019)

The effect of first chromosome long arm duplication on survival of endometrial carcinoma
por: Sever, Erman, et al.
Publicado: (2014)

Association of Type of Treatment Facility With Overall Survival After a Diagnosis of Head and Neck Cancer
por: Carey, Ryan M., et al.
Publicado: (2020)

Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States
por: Xu, Zihan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_smisj887i4on5smcle33qre8t0